leukemia, "The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises." - ATCC
cell karyotype
cancer
cell lineage
mesoderm
cell sex
F
treatment
None
treatment description
No special treatment or protocol applies
antibody
CCNT2
antibody antibodydescription
Goal polyclonal. Raised against an internal region of human CycT2a/b. Recommeded for detection of CycT2a/b of rat, mouse or human origin. Vendor recommeds it use for the folloiwng applications: WB, IF and ELISA. Antibody Target: CCNT2
antibody targetdescription
CycT2 is one of three cyclins that can form a heterodimer with cyclin-dependent kinase 9 (CDK9). The heterodimer is known as positive elongation factor b (P-TEFb) and is responsible for the phosphophorylation of Ser2 of the heptad repeat in the C-terminal domain of RNA polymerase II as well as the negative elongation factors DSIF (hSpt4/hSpt5) and NELF. Phosphorylation of RNA polymerase II and the negative elongation factors by P-TEFb promotes elongation. CycT2 contains a leucine rich domain capable of binding to the C-terminal domain of RNA polymerase II.